Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study

Basit Öğe Kaydı
dc.contributor.authorKarhan, O?ur Ur
dc.contributor.authorİleri, Serdar
dc.contributor.authorUrakçi, Zuhat
dc.contributor.authorSezgin, Yasin
dc.contributor.authorYıldırım, Umit
dc.contributor.authorÜnlü, Beyza
dc.contributor.authorDemir, Hacer
dc.date.accessioned2026-01-24T12:20:49Z
dc.date.available2026-01-24T12:20:49Z
dc.date.issued2025
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractBackground: Metastatic gastric cancer (GC) and gastroesophageal junction (GEJ) cancer are associated with a poor prognosis. Recent advancements in treatment have incorporated trastuzumab, anti-PD-1 agents, and anti-claudin therapies alongside chemotherapy (ChT), significantly improving outcomes. Contemporary studies predominantly employ doublet ChT as the backbone for these regimens, although historically triplet ChT regimens have been favored, particularly in younger patients requiring rapid tumor shrinkage. Objective: The aim of this study was to compare the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of advanced GC and GEJ adenocarcinoma. Design: This was a retrospective multicenter study. Methods: Patient data were obtained from the databases of 25 hospitals across Turkey. Demographic and clinicopathological characteristics were documented. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan–Meier method, and group discrepancies were assessed with log-rank test. Results: A total of 493 patients were included in the analysis, with similar baseline characteristics between the two groups. The objective response rate was 36.3% in the mDCF group and 38% in the mFOLFOX-6 group (p?=?0.7). The median PFS was 6?months for mDCF and 7?months for mFOLFOX-6 (p?=?0.2), while the median OS was 12?months for mDCF and 11?months for mFOLFOX-6 (p?=?0.4). Grade 3–4 neutropenia occurred in 27.6% of patients treated with mDCF versus 17.8% with mFOLFOX-6 (p?=?0.01). Likewise, grade 3–4 anemia was more frequent in the mDCF group (9.5%) compared to the mFOLFOX-6 group (4.8%; p?=?0.04). Conclusion: Modified FOLFOX-6 demonstrated comparable efficacy to mDCF in the treatment of advanced GC and GEJ adenocarcinoma. Moreover, mFOLFOX-6 was associated with a lower incidence of hematological adverse effects. © The Author(s), 2025. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
dc.identifier.doi10.1177/17588359251368069
dc.identifier.issn1758-8340
dc.identifier.scopus2-s2.0-105014781950
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1177/17588359251368069
dc.identifier.urihttps://hdl.handle.net/20.500.12868/4602
dc.identifier.volume17
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherSAGE Publications Inc.
dc.relation.ispartofTherapeutic Advances in Medical Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20260121
dc.subjectchemotherapy
dc.subjectgastric cancer
dc.subjectmetastasis
dc.subjectquality of life
dc.subjectsurvivorship
dc.subjecttoxicity management
dc.titleComparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu